Tango Therapeutics and Erasca have begun enrolment for a Phase I/II trial assessing the combination of oral therapies ERAS-0015 and vopimetostat in patients with lung and pancreatic cancers.
The multi-centre, open-label trial focuses on individuals diagnosed with methylthioadenosine phosphorylase (MTAP)-deleted pancreatic ductal adenocarcinoma, alongside patients with MTAP-deleted and rat sarcoma virus (RAS)-mutant non-small cell lung cancer.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
It is sponsored by Tango Therapeutics and consists of dose-escalation and expansion phases.
The dose-escalation phase primarily aims to identify the combination’s maximum tolerated dose.
Secondary measures include evaluating safety, tolerability, pharmacokinetics, and antitumour activity.
Tango Therapeutics president and CEO Malte Peters said: “The encouraging clinical activity, durability and tolerability observed to date with vopimetostat in combination with RAS inhibition reinforce our belief that co-targeting PRMT5 and RAS represents a promising new frontier in the treatment of pancreatic cancer and potentially other RAS-driven cancers.
“We are thrilled to initiate this study in partnership with Erasca, a company leading the advancement of RAS-targeted therapies, to evaluate vopimetostat with ERAS-0015 and further explore the potential of this clinically validated and synergistic combination approach.”
Both investigational therapies target cancer pathways through distinct mechanisms.
ERAS-0015 is an oral pan-RAS molecular glue created to block RAS signalling and counter resistance to mutant-selective inhibitors by suppressing RAS wild-type variants.
Erasca is currently assessing the therapy in the AURORAS-1 Phase I trial for patients presenting with RAS-mutant solid tumours.
Initial dose escalation demonstrated linear pharmacokinetics alongside confirmed and unconfirmed partial responses at doses starting at 8mg once daily.
Vopimetostat is a once-daily oral protein arginine methyltransferase 5 (PRMT5) inhibitor evaluated by Tango Therapeutics as both a monotherapy and in combination.
In clinical evaluations to date, the therapy showed durable activity and a favourable tolerability profile across several MTAP-deleted cancers, including pancreatic and lung malignancies.
